Dr. Kalpesh Barot, MD Joins ADIA Nutrition, Completing Phase One

WINTER PARK, Fla., Sept. 24, 2024 – ADIA Nutrition (OTC Pink: ADIA) is pleased to introduce the newest addition to its Board of Medical Directors, Dr. Kalpesh Barot, MD, a highly esteemed oncologist from the Southwest Cancer Center. This appointment was endorsed unanimously by the Board, which is steered by Dr. Monica Sher, MD, and Dr. Richard Edwards, DO, in light of Dr. Barot’s outstanding qualifications and extensive experience.

Dr. Barot’s remarkable background in oncology will significantly bolster ADIA Nutrition’s mission to enhance healthcare solutions. He will oversee ADIA’s aHSCT (autologous hematopoietic stem cell transplantation) treatments, an innovative therapy aimed at providing new hope for patients grappling with Multiple Sclerosis (MS).

“Dr. Barot’s addition to our Board is a pivotal moment for ADIA Nutrition,” commented Dr. Monica Sher, MD, Chair of the Board. “His extensive expertise in oncology and dedication to patient care align seamlessly with our vision to offer groundbreaking and effective therapies for MS patients. We are certain that his input will propel our mission of revolutionizing patient outcomes with advanced therapeutic solutions.”

Dr. Barot brings a wealth of knowledge acquired from his tenure at the Southwest Cancer Center to ADIA Nutrition’s already capable team of medical professionals. His role will be integral in refining the aHSCT protocols and ensuring the highest standards of patient care during this transformative treatment.

According to Board member and CEO Larry Powalisz, “Appointing Dr. Barot to our Board underscores our commitment to continuously enhancing the quality and breadth of our medical leadership. His oncology background will be crucial in perfecting our aHSCT programs and broadening the scope of treatment for MS patients.”

With the medical board now complete, ADIA Nutrition is poised to establish and refine all protocols and procedures for their aHSCT treatment for MS. The assembled expertise of the board will guide the development of these protocols, aiming to make aHSCT a more accessible and effective treatment option for MS.

ADIA Nutrition Inc. is a publicly traded company dedicated to transforming healthcare and supplementation. The company focuses on innovation and quality through two main divisions: a supplement division that offers premium, organic supplements, and a medical division that specializes in Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments for Multiple Sclerosis (MS). ADIA Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.